narcotic medication assisted substance abuse treatment in
consultation with the appropriate State agencies, including,
but not limited to, the Department of Drug and Alcohol
Programs, the Department of Human Services, the Department of
Health, the Pennsylvania Board of Probation and Parole and
the Pennsylvania Commission on Crime and Delinquency.
(4) Make a form available to providers to be used to
confirm that an offender is eligible for and enrolled in the
pilot program.
(5) SET FORTH THE BASIS FOR MEDICAL PROVIDERS TO BE
REIMBURSED AND FOR MEDICAL PROVIDERS TO BE REIMBURSED FOR
COUNSELING SERVICES.
(5) (6) Promulgate any rules and regulations necessary
to implement this chapter.
(b) Limitation on grant awards.--Grant awards shall be at
the discretion of the department and shall be limited to amounts
annually appropriated to the department for the pilot program.
§ 4606. Prior authorization.
Long acting injectable naltrexone shall be approved as part
of a prior authorization process by any Medicaid managed care
plan operating under contract with the Commonwealth for eligible
offenders enrolled in the pilot program and receiving
comprehensive substance abuse treatment which includes the
monitoring of medication adherence upon their release from
county correctional institutions. Within 90 days of the
effective date of this section, the Department of Human Services
shall issue a bulletin notice to instruct Medicaid managed care
plans that approval for the use of long acting injectable
naltrexone must be granted if the eligible offenders are
enrolled in the pilot program upon their release from county
20150SB0524PN1443 - 6 -
<--
<--
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30